GC012F, Gracell Biotechnologies’ investigational dual FastCAR T-cell therapy, was safe and highly effective at eradicating cancer cells in people…
Somi Igbene, PhD
Somi graduated from Imperial College London in 2011 with a PhD in cellular and molecular immunology. She worked as a medical writer at several medical communications agencies in London, including Core Medica. Besides science writing, Somi works as a registered associate nutritionist, helping adults and children improve their diets to prevent type 2 diabetes.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Somi Igbene, PhD
Telo Genomics has teamed up with the Mayo Clinic to develop tests to help clinicians identify multiple myeloma (MM)…
The China National Medical Products Administration (NMPA) has agreed to review an application for Equecabtagene autoleucel — the country’s first…
Biohaven Pharmaceuticals has begun enrolling patients in its Phase 1a/1b trial testing the company’s antibody-recruiting molecule (ARM) called BHV-1100.